News
Topline data from both Phase 3 trials is expected in the second quarter of 2026, with NDA submission to follow thereafter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback